PT3137504T - Anticorpo que se liga a fcrn para tratar doenças autoimunes - Google Patents
Anticorpo que se liga a fcrn para tratar doenças autoimunesInfo
- Publication number
- PT3137504T PT3137504T PT157855008T PT15785500T PT3137504T PT 3137504 T PT3137504 T PT 3137504T PT 157855008 T PT157855008 T PT 157855008T PT 15785500 T PT15785500 T PT 15785500T PT 3137504 T PT3137504 T PT 3137504T
- Authority
- PT
- Portugal
- Prior art keywords
- fcrn
- autoimmune diseases
- antibody binding
- treating autoimmune
- treating
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101150050927 Fcgrt gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rehabilitation Therapy (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461986742P | 2014-04-30 | 2014-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3137504T true PT3137504T (pt) | 2023-08-18 |
Family
ID=54358928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157855008T PT3137504T (pt) | 2014-04-30 | 2015-04-30 | Anticorpo que se liga a fcrn para tratar doenças autoimunes |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US10544226B2 (enExample) |
| EP (2) | EP3137504B1 (enExample) |
| JP (1) | JP6449441B2 (enExample) |
| KR (2) | KR101954906B1 (enExample) |
| CN (2) | CN106459215B (enExample) |
| AU (2) | AU2015253915B2 (enExample) |
| CA (2) | CA2945086C (enExample) |
| DK (1) | DK3137504T5 (enExample) |
| EA (1) | EA038470B1 (enExample) |
| ES (1) | ES2952583T3 (enExample) |
| FI (1) | FI3137504T3 (enExample) |
| HU (1) | HUE062403T2 (enExample) |
| IL (2) | IL248159B (enExample) |
| MX (2) | MX382284B (enExample) |
| NZ (2) | NZ737666A (enExample) |
| PL (1) | PL3137504T3 (enExample) |
| PT (1) | PT3137504T (enExample) |
| RS (1) | RS64542B1 (enExample) |
| SA (1) | SA516380194B1 (enExample) |
| SG (1) | SG11201608208VA (enExample) |
| WO (1) | WO2015167293A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106957365B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| KR20190015704A (ko) * | 2016-04-25 | 2019-02-14 | 신티뮨, 인크. | 인간화된 친화성 성숙 항-fcrn 항체 |
| CA3032415A1 (en) * | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| JP6827113B2 (ja) | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． | シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用 |
| RU2020100880A (ru) * | 2017-06-15 | 2021-07-15 | Юсб Биофарма Срл | Способ лечения иммунной тромбоцитопении |
| AU2018386193B2 (en) | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| MX2021004351A (es) | 2018-10-16 | 2021-05-31 | UCB Biopharma SRL | Metodo para el tratamiento de miastenia grave. |
| EA202191231A1 (ru) * | 2018-11-06 | 2021-10-11 | Иммуновант Сайенси Гмбх | СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ |
| GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| WO2021101975A1 (en) | 2019-11-19 | 2021-05-27 | Immunovant Sciences Gmbh | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies |
| WO2021160116A1 (zh) * | 2020-02-10 | 2021-08-19 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
| EP4173637A4 (en) * | 2020-06-29 | 2024-08-07 | Hanall Biopharma Co., Ltd. | FORMULATION FOR ANTI-FCRN ANTIBODIES |
| CN116490208A (zh) * | 2020-08-06 | 2023-07-25 | 史坦利科西斯治疗有限责任公司 | Il-8抗体及其使用方法 |
| CN113484526B (zh) * | 2021-08-11 | 2024-08-23 | 上海迈晋生物医药科技有限公司 | 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法 |
| WO2023016538A1 (en) * | 2021-08-13 | 2023-02-16 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing fcrn and uses thereof |
| US20250026814A1 (en) * | 2021-11-16 | 2025-01-23 | The University Of Chicago | Polypeptides for detection and treatment of coronavirus infection |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| WO2023235679A1 (en) | 2022-05-30 | 2023-12-07 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| KR20250018382A (ko) | 2022-05-30 | 2025-02-05 | 한올바이오파마주식회사 | 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편 |
| JP2025526384A (ja) * | 2022-07-27 | 2025-08-13 | アブリンクス エン．ヴェー． | 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド |
| AU2023336199A1 (en) | 2022-09-06 | 2025-04-03 | Immunovant Sciences Gmbh | Methods of treating graves' disease using anti-fcrn antibodies |
| WO2024052358A1 (en) | 2022-09-06 | 2024-03-14 | Immunovant Sciences Gmbh | Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies |
| CN120882751A (zh) | 2023-03-08 | 2025-10-31 | 依牧诺万科学有限公司 | 含聚山梨酯赋形剂的高浓度蛋白质制剂及其制备方法 |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| WO2025017368A1 (en) | 2023-07-16 | 2025-01-23 | argenx BV | Methods of treating chronic inflammatory demyelinating polyneuropathy |
| WO2025093717A1 (en) | 2023-10-31 | 2025-05-08 | Immunovant Sciences Gmbh | Methods of improving anti-fcrn therapies |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| CN119490588A (zh) * | 2024-10-17 | 2025-02-21 | 广州康盛生物科技股份有限公司 | 一种抗人FcRn的VHH抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| JP2007501847A (ja) | 2003-08-08 | 2007-02-01 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体 |
| US7662928B2 (en) * | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| WO2006118772A2 (en) | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| EP2602323B1 (en) | 2007-06-01 | 2018-02-28 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |
| CA3131470A1 (en) * | 2008-04-25 | 2009-10-29 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| CN103619353B (zh) | 2011-06-02 | 2016-01-06 | 戴埃克斯有限公司 | Fc受体结合蛋白 |
| KR20130071961A (ko) * | 2011-12-21 | 2013-07-01 | 한올바이오파마주식회사 | ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| JP2016528167A (ja) | 2013-04-29 | 2016-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ヒトＦｃＲｎ結合改変抗体及び使用方法 |
| KR101815265B1 (ko) * | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
-
2015
- 2015-04-30 NZ NZ737666A patent/NZ737666A/en unknown
- 2015-04-30 EP EP15785500.8A patent/EP3137504B1/en active Active
- 2015-04-30 KR KR1020187023165A patent/KR101954906B1/ko active Active
- 2015-04-30 KR KR1020167032395A patent/KR101889466B1/ko active Active
- 2015-04-30 RS RS20230636A patent/RS64542B1/sr unknown
- 2015-04-30 DK DK15785500.8T patent/DK3137504T5/da active
- 2015-04-30 SG SG11201608208VA patent/SG11201608208VA/en unknown
- 2015-04-30 CN CN201580029793.2A patent/CN106459215B/zh active Active
- 2015-04-30 CA CA2945086A patent/CA2945086C/en active Active
- 2015-04-30 CN CN202010031615.6A patent/CN111138540B/zh active Active
- 2015-04-30 WO PCT/KR2015/004424 patent/WO2015167293A1/en not_active Ceased
- 2015-04-30 HU HUE15785500A patent/HUE062403T2/hu unknown
- 2015-04-30 FI FIEP15785500.8T patent/FI3137504T3/fi active
- 2015-04-30 AU AU2015253915A patent/AU2015253915B2/en active Active
- 2015-04-30 MX MX2016014210A patent/MX382284B/es unknown
- 2015-04-30 NZ NZ726089A patent/NZ726089A/en unknown
- 2015-04-30 US US15/301,948 patent/US10544226B2/en active Active
- 2015-04-30 EA EA201692192A patent/EA038470B1/ru unknown
- 2015-04-30 PL PL15785500.8T patent/PL3137504T3/pl unknown
- 2015-04-30 PT PT157855008T patent/PT3137504T/pt unknown
- 2015-04-30 EP EP23172456.8A patent/EP4241852A3/en active Pending
- 2015-04-30 ES ES15785500T patent/ES2952583T3/es active Active
- 2015-04-30 JP JP2017510285A patent/JP6449441B2/ja active Active
- 2015-04-30 CA CA3095295A patent/CA3095295C/en active Active
-
2016
- 2016-09-29 IL IL248159A patent/IL248159B/en active IP Right Grant
- 2016-10-28 MX MX2021005193A patent/MX2021005193A/es unknown
- 2016-10-30 SA SA516380194A patent/SA516380194B1/ar unknown
-
2018
- 2018-05-22 AU AU2018203582A patent/AU2018203582B2/en active Active
-
2019
- 2019-01-15 US US16/248,083 patent/US20190135917A1/en not_active Abandoned
- 2019-12-11 US US16/710,318 patent/US11613578B2/en active Active
-
2021
- 2021-02-03 IL IL280613A patent/IL280613B/en unknown
-
2023
- 2023-02-21 US US18/171,967 patent/US20230235063A1/en active Pending
- 2023-11-17 US US18/512,775 patent/US20240092913A1/en not_active Abandoned
-
2024
- 2024-07-03 US US18/763,278 patent/US20250026835A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280613B (en) | fcrn-binding antibodies for the treatment of autoimmune diseases | |
| IL285287A (en) | Antibodies to tigit | |
| IL267798B (en) | Human antibodies to pd-1 | |
| IL261188A (en) | Antibodies against tigit | |
| ZA201801427B (en) | Antibodies that specifically bind to tl1a | |
| IL252716A0 (en) | Anti-csf1r antibodies for the treatment of pvns | |
| SMT202100263T1 (it) | Anticorpi leganti protofibrille a-beta migliorati | |
| ZA201702985B (en) | Improved il-6 antibodies | |
| TWI560201B (en) | Bi-specific antibodies for treating cancer | |
| IL269394A (en) | Antibodies bind to STEAP-1 | |
| GB201521357D0 (en) | Methods for predicting response to anti-TNF therapy | |
| SG11201701997UA (en) | Compression of cascading style sheet files | |
| IL265178A (en) | Antibody for the treatment of autoimmune diseases |